NCT02586168View on ClinicalTrials.gov

The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

October 31, 2001

Study Completion Date

October 31, 2001

Conditions
Insulin Sensitivity
Interventions
DRUG

Gemcabene 900 mg

Gemcabene 900 mg once daily (QD)

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

NeuroBo Pharmaceuticals Inc.

INDUSTRY